Socialiya - Entertainment. Knowledge. Community.
ASCO: RevMed confident in Ras leadership as rivals square up

RevMed is using ASCO as a chance to spotlight the full data from the phase 3 trial of daraxonrasib,...

HEALTH NEWS May 31, 2026

ASCO: RevMed confident in Ras leadership as rivals square up

RevMed is using ASCO as a chance to spotlight the full data from the phase 3 trial of daraxonrasib, which took the world by storm earlier this year.

2 views 0 likes 0 comments
Share:
RevMed is using ASCO as a chance to spotlight the full data from the phase 3 trial of daraxonrasib, which took the world by storm earlier this year.

Author: Fierce Biotech

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya